Showing results (71-80 of 258) with videos related to

Sort By:
Pageof 26
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 12, 2004
Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patientsKoichi Azuma, Tetsuro Sasada, Hiroko Takedatsu, et al.
Cancer Immunology, Immunotherapy : CII|March 22, 2021
Clinical significance of peripheral TCR and BCR repertoire diversity in EGFR/ALK wild-type NSCLC treated with anti-PD-1 antibodyYoshiro Nakahara, Takaji Matsutani, Yuka Igarashi, et al.
General Thoracic and Cardiovascular Surgery Cases|November 9, 2024
A case of salvage surgery following chemoradiotherapy and durvalumab for initially unresectable superior sulcus tumor with N3 involvementTakehiko Manabe, Masatoshi Kanayama, Hiroki Matsumiya, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2016
A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancerKazuhiko Yamada, Masao Ichiki, Kazuhisa Takahashi, et al.
Investigational New Drugs|April 1, 2017
Aplastic anemia in a lung adenocarcinoma patient receiving pemetrexedGoushi Matama, Takaaki Tokito, Hiroaki Takeoka, et al.
Scientific Reports|November 5, 2016
Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer PatientsNorikazu Matsuo, Koichi Azuma, Kazuko Sakai, et al.
Thoracic Cancer|April 21, 2018
Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR-TKIsKen Masuda, Takaaki Tokito, Koichi Azuma, et al.
Oncotarget|August 14, 2014
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitorKoichi Azuma, Akihiko Kawahara, Kahori Sonoda, et al.
Plos One|August 14, 2013
Prognostic value of EGFR mutation and ERCC1 in patients with non-small cell lung cancer undergoing platinum-based chemotherapyFumie Yamashita, Koichi Azuma, Tsukasa Yoshida, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2016
Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapyTakaaki Tokito, Koichi Azuma, Akihiko Kawahara, et al.
Pageof 26